Company profile
Oramed Pharmaceuticals Inc.
NASDAQ: ORMP · Healthcare · Biotechnology
#796 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
61CFH 71DQ 49GM 57SS 57
v0.1 · 65/100 weight · provisional
↑ net margin, return on assets · ↓ filing timeliness, operating margin
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
$64.0M
Employees
13
as of 2026-08-14
Market cap
$179.3M
as of 2026-08-14
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$2.0M$2.0M2025
Net income$64.0M$64.0M2025
Operating income-$15.1M-$15.1M2025
Total assets$230.9M$230.9M2025
Equity$199.7M$199.7M2025
Revenue trend
FY2017 – FY2025 · USD
FY17
FY18
FY19
FY20
FY21
FY22
FY23
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Oramed Pharmaceuticals Inc.’s revenue?
Oramed Pharmaceuticals Inc. booked $2.0M in FY2025 revenue, growing 49% year over year — faster than most Healthcare companies we track, at a 3202.5% net margin.
Peers · Healthcare
Dianthus Therapeutics, Inc.49DCocrystal Pharma, Inc.31DSagimet Biosciences Inc.36DRapid Dose Therapeutics Corp.38DPressure BioSciences, Inc.——Lipocine Inc.48DNeighbors
New York →Key facts
CEONadav Kidron
SectorHealthcare
IndustryBiotechnology
HeadquartersNew York City, NY
ExchangeNASDAQ: ORMP
Employees13
IPO date2007-05-01
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.